Media Hypes Praluent, the Next Expensive “Blockbuster” Not Yet Shown to Benefit Patients
Another example of the corruption of science: the press falls all over itself hyping Praluent, a new cholesterol-lowering drug with remarkably inconclusive clinical trial data behind it. As Roy Poses points out, “The clinical benefit of the drug was not evident in this trial.”
Read more...